BPC-157 and TB-500 (Why the Stack Has No Established Dose)
By DoseGauge Editorial · Updated 2026-06-12 · 4 min read
The BPC-157 and TB-500 stack has no clinically established protocol and no evidence-based dose ratio. No controlled human trial has evaluated a fixed BPC-157 plus TB-500 combination, so any ratio you see online comes from informal community sources, not data. Researchers who work with both peptides calculate each one separately, because each has its own vial concentration. Neither compound is FDA-approved. This page explains why no blend dose exists and how the two are calculated independently. It does not recommend a stack or a dose.
What each compound is
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a protein found in human gastric juice. Its evidence base is almost entirely preclinical: cell-culture and animal studies of tissue repair and angiogenesis, with very limited human data. It is not FDA-approved.
TB-500 is a synthetic peptide fragment related to thymosin beta-4, a naturally occurring protein found in many mammalian tissues. Like BPC-157, it has been studied mainly in preclinical models, including work on angiogenesis and wound healing summarized in the thymosin beta-4 literature. It is also not FDA-approved, and thymosin beta-4 and its analogs are prohibited at all times in sport under the World Anti-Doping Agency Prohibited List.
The two are often discussed together because both have been studied preclinically for tissue-repair effects. That shared research theme is why communities pair them. It is not the same as evidence that the pair works together in people, which has not been established.
Why there is no established blend dose
A combination dose would need a controlled study that tested specific amounts of each peptide together and measured the result. No such human trial exists for BPC-157 plus TB-500. The reviews of each compound describe limited human data individually and none on a fixed combination. So when a forum or supplier lists a "BPC-157 and TB-500 dosage," that number is informal and community-derived. It is not validated, and it is not a recommendation.
Two practical consequences follow. First, there is no ratio to copy: the peptides have different molecular sizes, vial strengths, and informal reference doses, and nothing establishes a correct proportion between them. Second, mixing two compounds into a guessed ratio compounds the uncertainty that already exists for each one alone. The honest position is that the blend dose is unknown, and DoseGauge does not supply one.
Calculate each compound separately
Because each peptide has its own vial size and water volume, the only reliable approach is to calculate each one on its own. Reconstitute each vial, find each concentration, and convert each target dose to syringe units independently. The arithmetic is the same for both:
concentration = vial amount / water added
draw volume = dose / concentration
units (U-100) = draw volume x 100
Run BPC-157 through its calculator using your BPC-157 vial and water volume, then run TB-500 through its own calculator using the TB-500 vial and water volume. Keep the inputs separate; do not assume a number from one transfers to the other.
For the mixing steps, see how to reconstitute BPC-157. For the diluent, see what bacteriostatic water is. The conversion formulas are documented on the methodology page.
Frequently asked questions
What is the BPC-157 and TB-500 dosage for the blend?
There is no established blend dose. No controlled human trial has evaluated a fixed BPC-157 plus TB-500 combination, so no evidence-based ratio exists. The figures circulating online are informal and not a recommendation. Researchers who use both peptides calculate each separately from its own vial concentration. Discuss any research peptide with a licensed clinician.
Can you mix BPC-157 and TB-500 in the same syringe?
This page does not advise on co-administration, and no human trial establishes that practice. Because each peptide is reconstituted to its own concentration, the reliable way to get accurate units is to calculate each compound separately. Whether to combine research peptides at all is a question for a licensed clinician, not a calculator.
Are BPC-157 and TB-500 FDA-approved?
No. Neither BPC-157 nor TB-500 is approved by the FDA for any indication. Both are research peptides with evidence bases that are largely preclinical and very limited human data. TB-500 and related thymosin beta-4 substances are also prohibited at all times in sport under the World Anti-Doping Agency Prohibited List.
- Józwiak M et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide: Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMCID: PMC11859134.
- McGuire FP et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. PMCID: PMC12446177.
- Xing Y et al. Progress on the Function and Application of Thymosin Beta-4. Front Endocrinol (Lausanne). 2021;12:767785. PMCID: PMC8724243.
Informational and educational only. Not medical advice. DoseGauge computes from the values you enter and does not recommend a dose. Talk to a licensed clinician before using any peptide or GLP-1 medication.